GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

Used to treat advanced or recurrent endometrial cancer, Jemperli Dostarlimab, presents an opportunity to enhance the immune response against cancer cells when combined with chemotherapy. Get Your Free ...

Used to treat advanced or recurrent endometrial cancer, Jemperli Dostarlimab, presents an opportunity to enhance the immune response against cancer cells when combined with chemotherapy.

GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...

The surgical management of endometrial cancer has been markedly changed by minimally invasive techniques. After three decades of laparoscopy, robotic surgery has built upon and expanded the ...

La Comisión Europea ha aprobado el fármaco 'JEMPERLI' (dostarlimab), de GSK, en combinación con la quimioterapia estándar (carboplatino y paclitaxel) como tratamiento de primera línea para la ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...